Based on the effect of these HEA compounds on GNE enzyme activity and cellular functions that enhance cytoskeletal stability and lessen muscle wasting, we propose to explore them as therapeutic lead molecules for the treatment of GNE Myopathy, a rare neuromuscular disorder. The gene discussed is GNE; the disease is Distal myopathy, Nonaka type.